ArriVent BioPharma, Inc. — Form SCHEDULE 13D/A
Filed October 8, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 12/100
What the filing says
OrbiMed Advisors LLC, OrbiMed Asia GP IV L.P., OrbiMed Advisors IV Limited, and OrbiMed Capital GP VIII LLC jointly filed Amendment No. 2 to their Schedule 13D for ArriVent BioPharma common stock, dated October 6, 2026, executed October 8, 2026. The filing is a procedural joint filing agreement establishing responsibility for timeliness and accuracy; no specific shareholding changes, dollar amounts, or transaction details are disclosed in this exhibit.
Why this rating
Routine procedural amendment filing. No material business information, transaction, shareholding change, or strategic development disclosed here.
See more from October 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.